U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06879873) titled 'MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)(SURVEILLANCE-I)' on March 11.
Brief Summary: This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with stage I-III operable colon adenocarcinoma. MRD refers to the presence of cancer cells that remain in the body after treatment but are undetectable by traditional imaging methods. The study will use a blood-based test to detect circulating tumor DNA (ctDNA) and assess its ability to predict cancer recurrence and survival outcomes.
Patients who are newly diagnosed with stage I-III colon adenocarci...